Q3 FY2025 · ended Sep 30, 2025 · Revenue $2.79M, +4794.7% YoY · Filed Nov 13, 2025
Traws Pharma, Inc. (TRAW) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
$2.79M
+4794.7% vs year-ago quarter
Net income
$-3.05M
-233.8% vs year-ago quarter
Operating cash flow
$-7.50M
-25.5% vs year-ago quarter
Free cash flow
$-5.07M
+66.5% vs year-ago quarter
EPS
$-0.16
-45.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
15.37M
+117.6% vs year-ago quarter
Net cash
—
Operating margin
-554.6%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TRAW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Newtown, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1130598
- Former names
- Onconova Therapeutics, Inc. (until Apr 1, 2024); ONCONOVA THERAPEUTICS INC (until May 26, 2009)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
Q1 FY2025 Mar 31, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $2.8M | $2.7M | $57,000 |
| Operating income | -$3.2M | -$6.9M | -$4.1M | -$1.2M | -$5.2M |
| Net income | -$3.1M | -$7.1M | -$4.0M | -$915,000 | $21.5M |
| Diluted EPS | -$0.16 | -$0.53 | -$0.34 | -$0.11 | $2.09 |
| Operating cash flow | -$7.5M | -$2.6M | -$4.0M | -$6.0M | -$5.4M |
| Free cash flow | — | — | -$5.1M | — | — |
| Total assets | $11.5M | $8.2M | $12.4M | $15.6M | $19.1M |
| Total liabilities | $9.8M | $13.5M | $7.9M | $7.4M | $13.1M |
| Stockholders' equity | $1.7M | -$5.3M | $4.5M | $8.3M | $6.0M |
| Cash and investments | $5.0M | $3.1M | $6.4M | $13.1M | $15.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Oct 23, 2026 | Oct 23, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 14, 2026 | Aug 14, 2026 |
| 8-K |
Current report
Listing notice
|
Jul 31, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Other events
|
Jul 10, 2026 | Jul 10, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jul 9, 2026 | Jul 8, 2026 |
All 988 Traws Pharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.